Core Viewpoint - DeFi Technologies Inc. is under investigation for potential violations of federal securities laws, which may impact investors who have incurred losses [1] Investigation Details - The investigation is initiated by the Law Offices of Frank R. Cruz on behalf of investors [1] - The investigation follows a press release issued by DeFi on November 6, 2025, indicating possible issues related to compliance with securities regulations [1]

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy of its lead product candidate, nimacimab, during the class period from November 4, 2024, to October 3, 2025 [1] Company Overview - Skye Bioscience, Inc. is a clinical-stage biotechnology company based in San Diego, focusing on developing treatments for obesity and metabolic diseases [1] Legal Proceedings - The lawsuit claims that Skye failed to disclose that the efficacy of nimacimab was lower than represented, leading to an overstatement of the drug's clinical and commercial potential [1] - Investors who purchased Skye securities during the class period have until January 16, 2026, to seek appointment as lead plaintiff [1] Stock Performance - Following the announcement of topline data from a Phase 2a study on October 6, 2025, which revealed that the primary endpoint of an 8% weight loss difference compared to placebo was not met, Skye's stock price fell by $2.85 per share, or 60%, closing at $1.90 [1]

Core Viewpoint - The Stride, Inc. class action lawsuit alleges significant misconduct by the company and its executives, including fraudulent practices related to enrollment numbers and compliance failures, leading to substantial financial losses for investors [3][4][5]. Group 1: Allegations Against Stride, Inc. - The lawsuit claims that Stride inflated enrollment figures by retaining "ghost students" and cut staffing costs by overloading teachers beyond statutory limits [3]. - It is alleged that Stride ignored compliance requirements, including background checks and special education services, and suppressed whistleblowers who reported financial directives to delay hiring and deny services [3]. - A complaint from Gallup-McKinley County Schools Board of Education accused Stride of fraud and deceptive practices, which resulted in a nearly 12% drop in Stride's stock price [4]. Group 2: Financial Impact and Stock Performance - Following the announcement of "poor customer experience" leading to higher withdrawal rates and lower conversion rates, Stride estimated a loss of 10,000-15,000 enrollments, causing its stock price to plummet over 54% [5]. - The class action lawsuit allows investors who suffered losses during the specified Class Period to seek appointment as lead plaintiff, representing the interests of the class [6]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is leading the class action lawsuit, known for its significant recoveries in securities fraud cases, having secured over $2.5 billion for investors in 2024 alone [7].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of DeFi Technologies, Inc. securities, alleging that the company made false and misleading statements during the class period from May 12, 2025, to November 14, 2025, which negatively impacted investors [1][1][1] Summary by Relevant Sections Class Action Details - The class action lawsuit has already been filed, and investors who purchased DeFi Technologies securities during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][1][1] - Interested parties must move the court to serve as lead plaintiff by January 30, 2026 [1][1][1] Allegations Against DeFi Technologies - The lawsuit claims that DeFi Technologies faced delays in executing its DeFi arbitrage strategy, which was a key revenue driver [1][1][1] - It is alleged that the company understated the competition it faced from other digital asset treasury companies, impacting its ability to execute its strategy [1][1][1] - The lawsuit states that DeFi Technologies was unlikely to meet its previously issued revenue guidance for the fiscal year 2025 due to these issues [1][1][1] - Defendants allegedly downplayed the negative impact of these issues on the company's business and financial results, leading to materially false and misleading public statements [1][1][1] Rosen Law Firm's Background - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [1][1][1] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [1][1][1]

Core Viewpoint - Investors with significant losses in StubHub Holdings, Inc. have the opportunity to lead a securities fraud class action lawsuit against the company due to undisclosed financial issues related to its initial public offering in September 2025 [1]. Group 1: Lawsuit Details - The lawsuit alleges that StubHub failed to disclose changes in the timing of payments to vendors, which adversely affected its free cash flow [1]. - It is claimed that these undisclosed changes resulted in materially misleading reports regarding the company's free cash flow for the trailing 12 months [1]. - The positive statements made by the company about its business operations and prospects are asserted to be materially misleading and lacking a reasonable basis due to the undisclosed financial issues [1]. Group 2: Participation Information - Investors wishing to participate in the class action must contact the Law Offices of Howard G. Smith before January 23, 2026, which is the lead plaintiff deadline [1]. - Interested parties can reach out via email or telephone to discuss their legal rights and participation in the ongoing lawsuit [1].

Core Viewpoint - StubHub Holdings, Inc. is facing a class action lawsuit related to its September 2025 IPO, alleging violations of the Securities Act of 1933 due to misleading offering documents and significant financial discrepancies [1][3]. Company Overview - StubHub operates a global ticketing marketplace for live events and conducted its IPO on September 17, 2025, issuing approximately 34 million shares at an offering price of $23.50 per share [2][3]. Allegations of the Lawsuit - The lawsuit claims that the IPO's offering documents were materially false or misleading, omitting critical information about changes in payment timing to vendors, which adversely affected free cash flow [3]. - StubHub reported a free cash flow of negative $4.6 million for Q3 2025, marking a 143% decrease year-over-year, and a 69.3% decrease in net cash provided by operating activities [3]. - Following the release of these financial results, StubHub's stock price dropped nearly 21%, and by the time the lawsuit commenced, the stock was trading at $10.31, a nearly 56% decline from the IPO price [4][3]. Legal Process - Investors who purchased StubHub common stock in connection with the IPO can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6].

CARMAX STOCK ALERT: CarMax, Inc. (KMX) Investors Reminded to Contact BFA Law Prior to the January 2 Deadline in Securities Fraud Class ActionDecember 03, 2025 3:36 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 3, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against CarMax, Inc. (NYSE: KMX) and certain of the Company's senior executives for securities fraud after a significant stock dr ...

FREEPORT STOCK ALERT: Freeport-McMoRan Inc. (FCX) Investors Reminded to Contact BFA Law Prior to the January 12 Deadline in Securities Fraud Class ActionDecember 03, 2025 3:36 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 3, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Freeport-McMoRan Inc. (NYSE: FCX) and certain of the Company's senior executives for securities fraud after s ...

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Company Overview - Synopsys, Inc. specializes in design automation software products used for designing and testing integrated circuits. Its Design IP segment, which provides pre-designed silicon components, has been the fastest-growing segment, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. Financial Performance - In Q3 2025, Synopsys reported a revenue of $425.9 million for its Design IP segment, reflecting a 7.7% year-over-year decline. The net income was $242.5 million, marking a 43% year-over-year decline [6]. Customer Dynamics - The lawsuit alleges that contrary to Synopsys's claims of customer reliance on its IP to minimize integration risk, customers began requiring more customization for IP components, negatively impacting the economics of the Design IP business and threatening its business model [5]. Stock Market Reaction - Following the release of disappointing Q3 2025 results, Synopsys's stock price fell from $604.37 per share on September 9, 2025, to $387.78 per share on September 10, 2025, a decline of nearly 36% [6].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, particularly related to the company's clinical trial results and claims about its investigational drug sonelokimab [2][4]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, specifically through its investigational therapeutic sonelokimab [5]. Clinical Trials and Allegations - The company conducted Phase 3 VELA trials for sonelokimab, claiming strong clinical data and differentiation from competitors [6]. However, allegations suggest that the clinical data did not demonstrate a superior benefit over competitors, raising concerns about regulatory approval and commercial viability [7]. Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [8].